NOVARTIS for NOVARTIS
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Colombia Intellectual Property Regulatory Cooperation The North American Free Trade Agreement - NAFTA Re-negotiation USTR Special 301 Report/National Trade Estimate Trade Policy KORUS Tariffs CFIUS
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SARAH HALLER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Taxation/Internal Revenue Code TAX
ACA Pharmaceutical Industry Fee Exclusions Anti-Inversion Tax Medical Device Tax Repeal & Suspension Section 385 Tax Regulation Tax Reform Orphan Drug Tax Tax Reform Border Adjustment Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Surtax Interest Deduction Debt Equity Regulations Tax Cuts & Jobs Act Implementation Innovation Box Expanded FDII
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Copyright/Patent/Trademark CPT
Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents Inter Partes Review at PTO Biosimilars
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH New | — |
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Health Issues HCR
H.R.6948 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 Cell & Gene Therapy, including reimbursement Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs IPAB Generic Drug Labeling Outcomes-based Contracting PREA/BPCA Truthful, Non-Misleading Drug Information Part D Non-interference S.469 - Affordable and Safe Prescription Drug Importation Act Orphan Drugs Drug Pricing Transparency S.456 - RACE for Children Act S.204 - Trickett Wendler Right to Try Act of 2017 and related legislation Drug Compounding CMMI H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017 Clinical Trials H.R.2430 - FDA Reauthorization Act of 2017 H.R.849 - Protecting Seniors' Access to Medicare Act of 2017 Virtual Clinical Trials S2465 - Sickle Cell Disease Part D Donut Hole PAUSE Act DQSA Implementation Omnibus bill CR PAHPA Reauthorizing Biosimilar Pass Through Payments Value Based Pricing
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Foreign Relations FOR
Foreign Investment Risk Review Modernization Act of 2017 (FIRMMA) CFIUS Reform Foreign Agents Registration Act (FARA) Reform Treasury
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Medicare/Medicaid MMM
Biosimilars Medicare Part D Drug Pricing Part B Outcomes Based Contracts Generics Innovative Pharmaceuticals Cell and Gene Therapy Medicaid Alternative Payment Models
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Budget/Appropriations BUD
FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2018 Labor HHS Appropriations Bill Reconciliation Gx Drug Labeling Biosimilars 2018 Agriculture Appropriations Bill Importation Drug Pricing Value of Meds
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SHAWN O'NEAIL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.